Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C

Hepatitis C virus (HCV) infection is a heterogeneous disease, the natural history of which remains controversial. There is solid evidence that chronic HCV infection is responsible for the occurrence of hepatocellular carcinoma (HCC). The aim of the current cohort study was to determine the rate of the development of HCC from the time of primary HCV infection and to assess the risk factors for the development of HCC in chronic posttransfusion hepatitis C patients.

• Publication year

  2002

• Venue

  Cancer

• Publication date

  2002-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.10662PMID 12124834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical characteristics of patients in their 40s with HCV antibody-positive hepatocellular carcinoma.

  2000cited by this paper
• Management of cancer in the older person: a practical approach.

  2000cited by this paper
• Which patients with hepatitis C develop liver complications?

  2000cited by this paper
• Natural history of chronic hepatitis C

  2000cited by this paper
• Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C

  2000cited by this paper
• Natural history of hepatitis C: Its impact on clinical management

  2000cited by this paper
• Hepatocellular carcinoma in Austria: aetiological and clinical characteristics at presentation

  2000cited by this paper
• Management of Cancer in the Older Person : A Practical Approach

  2000cited by this paper
• Mechanisms and implications of the age‐associated decrease in DNA repair capacity

  2000cited by this paper
• The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

  1999cited by this paper
• Natural history of hepatitis C.

  1999cited by this paper
• Prevalence of hepatitis C virus infection in the United States.

  1999cited by this paper
• The long‐term outcomes of patients with compensated hepatitis C virus–related cirrhosis and history of parenteral exposure in the united states

  1999cited by this paper
• Gastric adenocarcinoma and kidney transplantation

  1998cited by this paper
• Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

  1998influential reference
• [The prevalence of hepatitis C virus infection].

  1998cited by this paper
• Determinants of outcome of compensated hepatitis C virus‐related cirrhosis

  1998cited by this paper
• Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

  1998cited by this paper
• Impact of alcohol on the histological and clinical progression of Hepatitis C infection

  1998influential reference
• Prognosis of chronic hepatitis c: Results of a large, prospective cohort study

  1998cited by this paper
• Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

  1998cited by this paper
• Natural history of hepatitis C

  1997cited by this paper
• Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

  1997cited by this paper
• The long‐term pathological evolution of chronic hepatitis C

  1996cited by this paper
• The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses

  1996cited by this paper
• Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion.

  1996cited by this paper
• Characteristic difference of hepatocellular carcinoma between hepatitis B‐ and C‐ viral infection in Japan

  1995cited by this paper
• Clinical outcomes after transfusion-associated hepatitis C.

  1995cited by this paper
• Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients

  1995cited by this paper
• Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

  1995cited by this paper
• Classification of chronic hepatitis: Diagnosis, grading and staging

  1994cited by this paper
• Epidemiology and long term prognosis of hepatitis C virus infection in Japan.

  1993cited by this paper
• A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis

  1993cited by this paper
• Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis.

  1993cited by this paper
• Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus

  1990influential reference
• The natural history of hepatitis.

  1969cited by this paper

• OPTIONS OF INTERFERON-FREE THERAPY FOR HCV INFECTION. A CASE STUDY. COMPARISON OF NON-INVASIVE METHODS FOR LIVER FIBROSIS ASSESSMENT

  2022cites this paper
• Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR

  2022cites this paper
• Epidemiological features of hepatitis B in the Russian Arctic

  2020cites this paper
• Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs

  2020cites this paper
• Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report

  2020cites this paper
• A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection

  2019cites this paper
• Direct-acting antivirals (daas) increase the serum vegf level in patients with chronic hepatitis c: a rationale for tumor recurrence

  2017cites this paper
• A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C

  2017cites this paper
• Liver Diseases in the Elderly

  2017cites this paper
• Value of expanding HCV screening and treatment policies in the United States.

  2016cites this paper
• Virologic responses and tolerance of peginterferon alfa plus ribavirin treatment for patients with chronic hepatitis C virus infection in different age categories

  2016cites this paper
• The clinical outcomes of chronic hepatitis C in South Korea

  2016cites this paper
• Epidemiología molecular del virus de la hepatitis C en Galicia: prevalencia y distribución de los genotipos virales en el área sanitaria de Santiago de Compostela

  2016cites this paper
• Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin

  2015cites this paper
• Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon‐based antiviral therapy

  2015cites this paper
• Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion‐acquired HCV infection

  2014cites this paper
• Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

  2014cites this paper
• Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.

  2014cites this paper
• Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes

  2014cites this paper
• Epidemiology and natural history of HCV infection

  2013cites this paper
• Characteristics of elderly hepatitis C virus‐associated hepatocellular carcinoma patients

  2013cites this paper
• Liver physiology and liver diseases in the elderly.

  2013cites this paper
• Prevention of Cancers Due to Infection

  2013cites this paper
• Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.

  2012cites this paper
• Experience of long-term low dose pegylated interferon therapy for chronic hepatitis C patients who cannot treat with standard of care therapy

  2012cites this paper
• The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients

  2012cites this paper
• Does Treatment Alter the Natural History of Chronic HCV

  2012cites this paper
• Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients.

  2011cites this paper
• Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy.

  2011cites this paper
• Chronic hepatitis C infection in the elderly

  2011cites this paper
• Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis

  2011cites this paper
• Clinical characteristics of hepatocellular carcinoma in elderly patients.

  2011cites this paper
• HCC develops even in the early stage of chronic liver disease in elderly patients with HCV infection.

  2010cites this paper
• Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

  2010cites this paper
• Increased rate of death related to presence of viremia among hepatitis C virus antibody–positive subjects in a community‐based cohort study

  2009cites this paper
• Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

  2009cites this paper
• Prognosis of hepatitis C virus‐infected Canadian post‐transfusion compensation claimant cohort

  2009cites this paper
• Virological Response in Patients with Hepatitis C Virus Genotype 1b and a High Viral Load

  2008cites this paper
• Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma

  2008cites this paper
• Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients

  2008cites this paper
• 1b型高ウイルス量高齢者C型慢性肝炎に対するPEG IFNα-2b/リバビリン治療（併用療法）の検討

  2008cites this paper
• Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: A meta‐analysis and meta‐regression

  2008cites this paper
• Alcohol drinking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population.

  2008cites this paper
• Efficacy of low dose long‐term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha‐fetoprotein: A pilot study

  2007cites this paper
• Is long‐term interferon monotherapy welcome news for older patients with chronic hepatitis C genotype 1?

  2007cites this paper
• Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

  2006cites this paper
• Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: Long term trends in Japan.

  2006cites this paper
• Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C

  2006cites this paper
• Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.

  2005cites this paper
• The epidemiology of hepatocellular carcinoma in hcv

  2005cites this paper
• Hepatitis C virus infection in the elderly

  2005cites this paper
• Factors associated with the initiation of alpha‐interferon treatment in Medicaid patients diagnosed with hepatitis C

  2005cites this paper
• National Prevention of Hepatocellular Carcinoma in Japan Based on Epidemiology of Hepatitis C Virus Infection in the General Population

  2005cites this paper
• Late liver‐related mortality from complications of transfusion‐acquired hepatitis C

  2005cites this paper
• Spread Times of Hepatitis C Virus Estimated by the Molecular Clock Differ among Japan, the United States and Egypt in Reflection of Their Distinct Socioeconomic Backgrounds

  2005cites this paper
• Hepatitis C Infection: A Clinical Review

  2004cites this paper
• The immune responsiveness in hepatitis C virus infected patients: effects of interferon-alfa/ribavirin combined treatment on the lymphocyte response with special reference to B cells.

  2004cites this paper
• Global burden of disease (GBD) for hepatitis C

  2004cites this paper
• Hepatocellular carcinoma: recent trends in Japan.

  2004cites this paper
• Global Burden of Disease (GBD) for Hepatitis C

  2004cites this paper
• Global Burden of Disease (GBD) for Hepatitis C The Global Burden of Hepatitis C Working Group

  2004cites this paper
• Habitual Betel Quid Chewing and Risk for Hepatocellular Carcinoma Complicating Cirrhosis

  2004cites this paper
• Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan.

  2003cites this paper
• Factores de riesgo para la progresión de la infección crónica de la Hepatitis viral C

  2003cites this paper
• Construction, package and identification of replication-deficient recombinant adenovirus expression vector of HCV C

  2003cites this paper
• Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes.

  2003cites this paper
• Impact of Aging on the Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection in Japan

  2003cites this paper
• Hépatite C : transmission nosocomiale, état de santé et devenir des personnes atteintes

  2003cites this paper